Godfrey Phillips India Enters 3-Year Distribution Agreement with Aspeya India for Nicotine Replacement Therapy Products
Godfrey Phillips India Limited approved a Distribution Agreement with Aspeya India Private Limited on 15th May 2026 for the distribution and re-sale of Nicotine Replacement Therapy products through domestic approved channels of trade. The initial term of the agreement is three years, subject to customary warranties and indemnities. Aspeya India, a related party entity linked to foreign promoter Philip Morris Global Brands Inc., USA, reported revenue from operations of Rs. 795.06 lakhs and profit after tax of Rs. 19.32 lakhs for the year ended 31st March 2025. The agreement is intended to leverage Godfrey Phillips India's distribution network to add to its top-line and bottom-line.

*this image is generated using AI for illustrative purposes only.
Godfrey Phillips India Limited has entered into a Distribution Agreement with Aspeya India Private Limited for the distribution and re-sale of Nicotine Replacement Therapy (NRT) products. The Board of Directors approved the agreement at its meeting held on 15th May 2026, which commenced at 2:45 PM and concluded at 4:00 PM. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Agreement Structure and Scope
Under the terms of the agreement, Godfrey Phillips India will purchase NRT products marketed by Aspeya India and subsequently distribute or re-sell them through approved channels of trade within the agreed domestic territory. The company will utilise its existing distribution set-up to facilitate this arrangement. The agreement is domestic in nature and does not involve any share exchange ratio or upfront consideration.
The key terms of the distribution agreement are summarised below:
| Parameter: | Details |
|---|---|
| Agreement Type: | Distribution Agreement |
| Products: | Nicotine Replacement Therapy (NRT) Products |
| Territory: | Domestic |
| Initial Term: | 3 (three) years |
| Scope: | Purchase and distribution/re-sale through approved channels of trade |
| Consideration: | Not Applicable |
| Share Exchange Ratio: | Not Applicable |
Related Party Disclosure
Aspeya India Private Limited is a member entity of the group to which Philip Morris Global Brands Inc., USA — the foreign promoter shareholder of Godfrey Phillips India — belongs. Accordingly, the transactions under the agreement qualify as related party transactions. The company has disclosed that all transactions shall be undertaken in the ordinary course of business and at arm's length, with the nature of concern or interest being financial.
Aspeya India — Financial Profile
Aspeya India is engaged in the business of marketing pharmaceutical and nutraceutical products in India. Based on its last available audited financials for the year ended 31st March 2025, the financial highlights are as follows:
| Metric: | Amount |
|---|---|
| Revenue from Operations: | Rs. 795.06 lakhs |
| Profit After Tax: | Rs. 19.32 lakhs |
Strategic Rationale
The agreement is expected to enable Godfrey Phillips India to leverage its established distribution infrastructure to distribute and re-sell Aspeya's NRT products. The company has indicated that this arrangement is anticipated to contribute positively to both its top-line and bottom-line performance. The agreement is subject to customary terms and conditions, including warranties and indemnities as set out in the agreement.
Historical Stock Returns for Godfrey Phillips
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.14% | -5.83% | +9.50% | -19.84% | -18.79% | +670.87% |
How might Godfrey Phillips India's entry into NRT distribution signal a broader strategic pivot toward reduced-risk or cessation products, and could this lead to similar agreements with other Philip Morris affiliates?
Given that Aspeya India reported only Rs. 795 lakhs in revenue for FY2025, what scale of distribution expansion would be needed for this agreement to materially impact Godfrey Phillips India's financials?
How could regulatory changes in India's NRT and pharmaceutical distribution landscape affect the viability and renewal of this three-year agreement beyond 2029?


































